Australian Clinical Labs (ASX:ACL) 1-Year Sortino Ratio: N/A (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ACL Australian Clinical Labs Ltd ASX:ACL
76 GF Score
Price A$2.80
GF Value A$2.95
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Australian Clinical Labs 1-Year Sortino Ratio?

The 1-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past year. As of today (2026-09-09), Australian Clinical Labs's 1-Year Sortino Ratio is Not available.


Australian Clinical Labs  (ASX:ACL) 1-Year Sortino Ratio Explanation

The 1-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by the standard deviation of negative returns over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.


Australian Clinical Labs 1-Year Sortino Ratio Related Terms


ASX:ACL vs TMO, DHR, NTRA: 1-Year Sortino Ratio Comparison

For the Diagnostics & Research subindustry, Australian Clinical Labs's 1-Year Sortino Ratio, along with its competitors' market caps and 1-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Australian Clinical Labs 1-Year Sortino Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's 1-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where Australian Clinical Labs's 1-Year Sortino Ratio falls into.


ASX:ACL
76GF Score
Australian Clinical Labs Ltd ASX:ACL
1-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Australian Clinical Labs 1-Year Sortino Ratio Calculation

The 1-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio over the past year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 1-Year Sortino Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the downside risks over one year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?

Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued. The current stock price of A$2.80 is trading 5.1% below its estimated GF Value™ of A$2.95. GuruFocus considers Australian Clinical Labs to be Fairly Valued.

Key valuation signals for ASX:ACL:

  • 1-Year Sortino Ratio: N/A
  • GF Value™: A$2.95 vs. price of A$2.80 (5.1% below fair value)
  • GF Score™: 76/100 with 9 warning signs

No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Australian Clinical Labs Business Description

Address 1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
76GF Score

Get the complete analysis for ASX:ACL

1-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.80
Price
A$2.95
GF Value